Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...

including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first ...

Apogee Therapeutics, Inc., a clinical-stage biotechnology company, announced the first patient has been dosed in the Part B portion of the phase 2 APEX clinical trial of APG777 in patients with ...

including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&I indications, today announced the first patient ...

Lilly’s drug becomes an oral alternative to Sanofi and Regeneron’s biologic therapy Dupixent (dupilumab), which was recommended as a second-line option for moderate to severe atopic dermatitis ...

Atopic dermatitis is a chronic inflammatory skin disease affecting a growing number of people worldwide. Marked by persistent ...

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.